NEW YORK (GenomeWeb) – Myriad Genetics today announced that it has partnered with Quanterix to create immunoassay services based on Quanterix's Simoa platform.

Myriad RBM, a wholly owned subsidiary of Myriad Genetics, will offer Simoa assay services for the study of inflammatory and autoimmune diseases. Quanterix's Simoa technology uses single molecule measurement to detect protein biomarkers in blood samples. Myriad RBM has manufactured and validated Simoa-based quantitative immunoassays for interleukin-6 and tumor necrosis factor alpha, the firm said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Even when given the option, not too many authors choose double-blinded peer-review for their manuscripts, ScienceInsider reports.

In PNAS this week: transcriptional read-through in stressed cells, genome stability role for the epigenetic regulator CTCF, and more.

The Save the Redwoods League is teaming with researchers to sequence the genomes of the coast redwood and giant sequoia.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.